Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $8.7 million.

  • Niagen Bioscience's Accumulated Expenses fell 929.94% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 929.94%. This contributed to the annual value of $7.8 million for FY2024, which is 1765.51% down from last year.
  • As of Q3 2025, Niagen Bioscience's Accumulated Expenses stood at $8.7 million, which was down 929.94% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Accumulated Expenses registered a high of $10.5 million during Q1 2024, and its lowest value of $5.6 million during Q2 2021.
  • Its 5-year average for Accumulated Expenses is $8.0 million, with a median of $8.1 million in 2022.
  • In the last 5 years, Niagen Bioscience's Accumulated Expenses skyrocketed by 3607.16% in 2023 and then crashed by 1765.51% in 2024.
  • Quarter analysis of 5 years shows Niagen Bioscience's Accumulated Expenses stood at $6.5 million in 2021, then increased by 13.21% to $7.3 million in 2022, then rose by 29.39% to $9.5 million in 2023, then decreased by 17.66% to $7.8 million in 2024, then rose by 11.3% to $8.7 million in 2025.
  • Its Accumulated Expenses stands at $8.7 million for Q3 2025, versus $7.4 million for Q2 2025 and $9.0 million for Q1 2025.